Most Clicked StoriesMore >


Federal rule on mail order limits patient choice, could put health at risk

PCMA SmartBrief | Dec 23, 2014

HHS' proposed regulation that would restrict the use of mail-order and specialty mail-order pharmacies could deny patients less costly options for getting their medicines. Mail-order pharmacy is safer and preferred by many patients. "People love it -- they love the convenience and the savings and the ease of handling," said PCMA President and CEO Mark Merritt. New York Times (tiered subscription model), The (12/23)


AbbVie sets $83,319 price for 12-week regimen of hepatitis C drug Viekira Pak

PCMA SmartBrief | Dec 22, 2014

Payers put drugmakers on notice

PCMA SmartBrief | Dec 23, 2014

Approval of new drug gives hepatitis C patients more cost-saving options

PCMA SmartBrief | Dec 22, 2014

Options open up for hepatitis C patients, specialists say

PCMA SmartBrief | Dec 24, 2014

White paper: FDA's impact on competition in prescription drug pricing

PCMA SmartBrief | Dec 22, 2014

Study: CDHP enrollees more likely to check prices, ask for generics

PCMA SmartBrief | Dec 23, 2014

Diabetes drugs approved based on surrogate endpoints

PCMA SmartBrief | Dec 23, 2014

Medicaid rolls expand even where eligibility did not

PCMA SmartBrief | Dec 22, 2014

Preferred networks hold premiums steady

PCMA SmartBrief | Dec 22, 2014


Find PCMA SmartBrief Issues by Date:



PCMA News More >


PCMA SmartBrief will not publish during the holidays

PCMA SmartBrief | Dec 24, 2014




Sign up for PCMA SmartBrief



Designed specifically for PBM industry professionals, PCMA SmartBrief is a FREE, daily e-mail newsletter. It provides the the most relevant and actionable PBM industry news in a quick, easy to read format. Learn more